BioSenic SA Logo

BioSenic SA

Develops therapies for autoimmune diseases, inflammation, and bone disorders.

BIOS | BR

Overview

Corporate Details

ISIN(s):
BE0970179827 (+1 more)
LEI:
549300HFIIMTOP1DFR76
Country:
Belgium
Address:
RUE GRANBONPRÉ 11, 1435 MONT-ST-GUIBERT

Description

BioSenic SA is a biotechnology company focused on developing innovative treatments for autoimmune diseases, inflammatory conditions, and bone disorders. The company's core activities are centered on two main technology platforms: one based on arsenic trioxide (ATO) for its immunomodulatory properties, and another involving allogeneic cell therapy for tissue repair and regeneration. BioSenic's objective is to address significant unmet medical needs in the fields of regenerative and immune medicine by advancing its clinical assets through development.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-12-01 17:20
BioS - 2nd EGM - Signed deed(1525437.1).pdf
French 2.4 MB
2025-11-12 10:00
BioSenic SA_Proxy EGM_FR_OC draft 2025 11 07(1518280.1).pdf
French 322.9 KB
2025-11-12 10:00
BioSenic - Expédition - 30.10.2025.pdf
French 653.3 KB
2025-11-12 10:00
BioSenic SA_Convening notice_2025_FR_2025 11 04(1506176.1).pdf
French 302.6 KB
2025-11-12 10:00
BioSenic SA_ Information on shareholders' rights EGM_FR_2025 11 07(1506226.1).p…
French 152.9 KB
2025-11-12 10:00
BIOS_PR_GMs-2025_FR_2025 11 07(1506246.1).pdf
French 214.9 KB
2025-11-12 10:00
BioSenic - Expédition - 30.10.2025.pdf
French 653.3 KB
2025-11-12 10:00
BioSenic - Expédition - 30.10.2025.pdf
French 653.3 KB
2025-10-28 07:00
BIOS_H1-PR Report_FR_2025 10 28_final.pdf
French 371.5 KB
2025-09-29 22:00
BioSenic SA_ Information on shareholders' rights GMs_FR_2025 09 29.pdf
French 160.6 KB
2025-09-29 22:00
BioSenic - (FR) Warrant_Plan - 2025 09 29.pdf
French 316.3 KB
2025-09-29 22:00
BioSenic - Rapport de gestion - 20250929-final.pdf
French 616.8 KB
2025-09-29 22:00
BioSenic SA-rapport du commissaire-31 12 2024_signed.pdf
French 1.6 MB
2025-09-29 22:00
BioSenic___Rapport_spécial_CA_(Art_7_228_CSA)_2025_09_29.docx.pdf
French 348.2 KB
2025-09-29 22:00
20250817_Rapport annuel 2024_FR_Final.pdf
French 2.0 MB

Automate Your Workflow. Get a real-time feed of all BioSenic SA filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for BioSenic SA

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for BioSenic SA via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-08-16 Rieger Francois Board Sell 2,500,000 25,000.00 EUR
2024-08-06 Rieger Francois Board Sell 868,653 7,186.87 EUR
2024-08-05 POMI SCHNEITER VERONIQUE Board Sell 534,750 4,331.47 EUR
2024-08-02 POMI SCHNEITER VERONIQUE Board Sell 193,900 1,609.37 EUR
2024-08-01 Rieger Francois Board Sell 1,236,684 11,463.87 EUR
2024-08-01 POMI SCHNEITER VERONIQUE Board Sell 140,003 1,246.03 EUR
2024-07-31 POMI SCHNEITER VERONIQUE Board Sell 503,771 4,685.07 EUR
2024-07-30 POMI SCHNEITER VERONIQUE Board Sell 360,021 3,348.20 EUR
2024-07-29 POMI SCHNEITER VERONIQUE Board Sell 372,893 3,430.62 EUR
2024-07-24 POMI SCHNEITER VERONIQUE Board Sell 2,168,361 21,033.10 EUR

Peer Companies

IVIM Technology, Inc. Logo
Provides intravital microscopy systems and CRO services for biomedical research.
South Korea
460470
IXICO PLC Logo
Provides AI-driven neuroimaging and data analytics for neuroscience clinical trials.
United Kingdom
IXI
Jade Biosciences, Inc. Logo
A clinical-stage biotech developing therapies for autoimmune and inflammatory diseases.
United States of America
JBIO
Jasper Therapeutics, Inc. Logo
A clinical-stage biotech developing therapies targeting mast and hematopoietic stem cells.
United States of America
JSPR
J. Molner AS Logo
A CDRO developing generic sterile injectable and dermatological dosage forms.
Estonia
JML
Kadimastem Ltd. Logo
Clinical-stage cell therapy company developing treatments for ALS and diabetes.
Israel
KDST
KAINOS MEDICINE, INC. Logo
Develops small molecule therapeutics for neurodegenerative, infectious, and oncological diseases.
South Korea
284620
Kairos Pharma, LTD. Logo
Develops oncology therapies targeting drug resistance and immune suppression.
United States of America
KAPA
Kancera Logo
Pharmaceutical company seeking a reverse takeover to leverage its public listing.
Sweden
KAN
KAZIA THERAPEUTICS LTD Logo
Oncology-focused biotech developing targeted therapies for cancers with high unmet needs.
United States of America
KZIA

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.